Flash e-reader

 Go to e-reader chapter








PDF FormatRequires Adobe Acrobat Reader

Table 9.6d

Immunosuppression Use for Maintenance by Regimen

Prior to Discharge, 2000 to 2009

Recipients with Liver Transplants

  Transplant Year
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Functioning Graft at Discharge 4,324 4,573 4,778 5,121 5,623 5,865 6,127 6,000 5,880 5,920
With Immunosuppression Info 4,310 4,567 4,775 5,116 5,595 5,796 6,062 5,965 5,840 5,909
CyA 0.2% 0.7% 0.2% 0.4% 0.2% 0.2% 0.1% 0.1% 0.2% 0.2%
Tac 1.5% 3.4% 4.8% 7.6% 9.8% 10.0% 5.6% 4.8% 3.7% 3.9%
--- + MMF/MPA 0.0% 0.1% 0.1% 0.3% 0.3% 0.2% 0.3% 0.2% 0.1% 0.2%
CyA + MMF/MPA 0.3% 0.2% 0.2% 0.4% 0.8% 0.6% 0.9% 1.2% 0.9% 0.8%
Tac + MMF/MPA 2.5% 2.6% 2.8% 6.5% 6.3% 8.5% 12.9% 15.6% 13.7% 12.4%
--- + OtherAntimet 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + OtherAntimet 0.0% 0.0% 0.1% 0.5% 0.5% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + OtherAntimet 0.1% 0.1% 0.0% 0.3% 0.3% 0.3% 0.1% 0.2% 0.0% 0.1%
CyA + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + MMF/MPA + OtherAntimet 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + Siro/Evero 0.0% 0.0% 0.1% 0.1% 0.1% 0.2% 0.1% 0.1% 0.0% 0.0%
CyA + Siro/Evero 0.6% 0.4% 0.0% 0.0% 0.0% 0.3% 0.6% 0.5% 0.3% 0.3%
Tac + Siro/Evero 1.0% 1.1% 0.4% 0.2% 0.4% 0.1% 0.2% 0.1% 0.1% 0.1%
--- + MMF/MPA + Siro/Evero 0.0% 0.0% 0.1% 0.2% 0.1% 0.1% 0.2% 0.2% 0.3% 0.2%
CyA + MMF/MPA + Siro/Evero 0.0% 0.0% 0.0% 0.1% 0.0% 0.0% 0.0% 0.1% 0.0% 0.0%
Tac + MMF/MPA + Siro/Evero 0.0% 0.2% 0.1% 0.2% 0.1% 0.1% 0.1% 0.1% 0.0% 0.0%
--- + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
CyA + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
Tac + OtherAntimet + Siro/Evero 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%
--- + Steroids 2.8% 2.2% 0.8% 0.8% 1.4% 0.8% 0.6% 0.5% 1.1% 2.2%
CyA + Steroids 6.1% 2.6% 2.1% 1.4% 1.0% 1.1% 0.5% 0.7% 0.4% 0.6%
Tac + Steroids 32.1% 32.3% 35.4% 29.4% 26.2% 24.1% 21.5% 19.5% 16.1% 16.1%
--- + MMF/MPA + Steroids 0.6% 0.9% 0.9% 0.9% 1.2% 0.9% 1.0% 0.7% 1.0% 1.2%
CyA + MMF/MPA + Steroids 6.6% 5.5% 4.6% 3.8% 3.3% 3.1% 3.0% 3.0% 3.5% 3.4%
Tac + MMF/MPA + Steroids 30.5% 35.1% 36.6% 39.5% 41.4% 44.8% 48.1% 49.2% 55.3% 54.0%
--- + OtherAntimet + Steroids 0.0% 0.0% 0.0% 0.3% 0.0% 0.0% 0.0% 0.0% 0.0% 0.1%
CyA + OtherAntimet + Steroids 2.6% 1.2% 1.2% 0.1% 0.5% 0.2% 0.1% 0.1% 0.1% 0.1%
Tac + OtherAntimet + Steroids 1.9% 1.4% 2.0% 1.8% 0.6% 0.1% 0.1% 0.2% 0.2% 0.7%
--- + Siro/Evero + Steroids 0.4% 0.4% 0.4% 0.2% 0.3% 0.2% 0.2% 0.1% 0.1% 0.2%
CyA + Siro/Evero + Steroids 0.4% 0.3% 0.6% 0.5% 0.4% 0.3% 0.1% 0.1% 0.2% 0.1%
Tac + Siro/Evero + Steroids 4.5% 4.6% 2.6% 1.0% 1.4% 0.9% 1.0% 0.4% 0.3% 0.2%
Other Regimen 5.0% 4.7% 3.9% 3.4% 3.1% 2.8% 2.4% 2.2% 2.3% 2.8%


Source: OPTN/SRTR Data as of October 1, 2010.

Percentages in each column sum to 100 percent.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.